# Elantas Beck India share price today (Elantas Beck India Ltd, NSE: ELANTAS)

> Elantas Beck India share price today: ₹12,756.00 at the NSE close on 3 November 2026, up 32.9% in a year. Elantas Beck India (NSE: ELANTAS) is worth ₹10,112 crore, trades at a P/E of 54.1 and has closed between ₹7,570.60 and ₹14,521.35 over the past 52 weeks. > Elantas Beck India Ltd's share price has risen faster than its earnings: +32.9% in a year, against +5.9% for earnings per share. ELANTAS · Chemicals - Organic · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/elantas-beck-india-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from fewer quarters than usual
- Price: ₹12,756.00 (+32.9% in a year)
- P/E: 54.1× (higher than 81% of the last 11 years)
- Revenue (Sep 2026): ₹265 Cr (+22.1% on a year ago)
- Profit (Sep 2026): ₹46.0 Cr (+27.8% on a year ago)
- Operating margin: 23.0% (+1.0 points on a year ago)
- ROCE: 21%, FY25
- Profit that came in as cash: 76%, last 3 years

The main question: the share price moved +32.9% in a year while yearly earnings per share moved +5.9%. The difference came from the market paying a higher multiple. ## What is the Elantas Beck India share price today? Elantas Beck India Ltd's share price was ₹12,756.00 at the close on 3 November 2026. It has been rising for 19 weeks. That is 14.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹7,571 and ₹14,521, and at that close it sat 75% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 15 weeks in a row. Over the last 11 years the share price moved +893% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Elantas Beck India this quarter? Two changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare) and indian funds and insurers (DIIs) raised their stake for 4 quarters in a row. 1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹265 crore, +22.1% on a year earlier. 2. Indian funds and insurers (DIIs) raised their stake for 4 quarters in a row From 12.2% to 12.5% of the company by the September 2026 quarter. ## What are Elantas Beck India's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Elantas Beck India reported revenue of ₹265 crore, up 22.1% from ₹217 crore a year earlier, and a profit of ₹46.0 crore, up 27.8% from ₹36.0 crore. ### Elantas Beck India results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹265 crore | ₹217 crore | +22.1% |
| Profit | ₹46.0 crore | ₹36.0 crore | +27.8% |
| Earnings per share | ₹57.46 | ₹45.74 | +25.6% |
| Operating margin | 23.0% | 22.0% | +1.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Elantas Beck India share price history? Elantas Beck India closed at ₹12,756.00 on 3 November 2026, up 32.9% from ₹9,600.05 a year earlier (31 October 2025) and up 247.6% over five years. Its highest weekly close since March 2016 was ₹14,521.35 on 11 September 2026. ### Elantas Beck India share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹12,234.00 | +4.3% |
| 1 month ago · 1 Oct 2026 | ₹13,442.20 | −5.1% |
| 6 months ago · 30 Apr 2026 | ₹9,624.20 | +32.5% |
| 1 year ago · 31 Oct 2025 | ₹9,600.05 | +32.9% |
| 3 years ago · 3 Nov 2023 | ₹7,801.40 | +63.5% |
| 5 years ago · 4 Nov 2021 | ₹3,670.10 | +247.6% |
| 10 years ago · 4 Nov 2016 | ₹1,802.15 | +607.8% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹1,285.00 | +892.7% |
| Highest weekly close since March 2016, also the 52-week high · 11 Sep 2026 | ₹14,521.35 | −12.2% |
| Lowest weekly close since March 2016 · 18 Mar 2016 | ₹1,265.50 | +908.0% |
| 52-week low (weekly close) · 20 Mar 2026 | ₹7,570.60 | +68.5% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (558 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Elantas Beck India? 3 Nov 2026: Elantas Beck India closed at ₹12,756.00, up 4.3% on the week and down 5.1% on the month. Results for July to September 2026: Revenue up 22.1% and profit up 27.8% on a year earlier. ### Earlier

- 5 May 2026: ex-date for a dividend of ₹7.50 a share. ## What dividend does Elantas Beck India pay? Elantas Beck India paid ₹7.50 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.06% at the ₹12,756.00 close on 3 November 2026. The last was a dividend of ₹7.50 a share, ex-date 5 May 2026. ### Elantas Beck India dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 5 May 2026 | ₹7.50 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 0 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Elantas Beck India Ltd paid out 4% of its profit as dividends in FY25, and it paid a dividend in each of its last 12 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Elantas Beck India on? Elantas Beck India is on one of our India lists: Momentum stocks. [Momentum stocks Market cap cr: 10368.438014584803](https://www.sectoralpha.in/momentum-stocks-india)

## Is Elantas Beck India profitable? Elantas Beck India Ltd earned ₹46.0 Cr of net profit in the Sep 2026 quarter, +27.8% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was ₹148 Cr. Over 10 years profit has grown 13.4% a year on average. That is 17.4% of the quarter's revenue. The same quarter a year earlier earned ₹36.0 Cr. For the full year, FY25 profit was ₹148 Cr (+5.7% on the year before). Why profit moved: revenue changed +22.1% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +33.5% and revenue +18.4%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Elantas Beck India make, and is it growing? Elantas Beck India Ltd reported ₹265 Cr of revenue in the Sep 2026 quarter, +22.1% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 9.4% a year on average. The last full year, FY25, came in at ₹848 Cr. The last four reported quarters add to ₹985 Cr. FY25 revenue was ₹848 Cr, +13.2% on the year before. Recent pace: the last four quarters grew +18.4% on average, against 9.4% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +18.7%, against +16.5% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +35.5%, against +12.8% a year (accelerating). ## How much of every ₹100 of sales does Elantas Beck India keep? Elantas Beck India Ltd's operating margin was 23.0% in the Sep 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Across 12 years it has been between 12.0% and 22.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +1.2 percentage points on the year while gross margin changed +0.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Elantas Beck India's profit turning into cash? Over the last 3 years, 76% of Elantas Beck India Ltd's reported profit came in as cash from its operations, so most of the profit is real cash. In FY25 it brought in ₹127 Cr of operating cash against ₹148 Cr of profit. After ₹27.0 Cr of spending on assets, ₹100 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 76% of profit came in as cash: the cash cycle got 16 days longer between FY20 and FY25, so more of each rupee of profit waits in the business before it arrives. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 16 days longer. The next section looks at where the cash is stuck. ## Where does Elantas Beck India's cash go? Elantas Beck India Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 70 days in FY25, up from 54 days in FY20. It spent ₹185 Cr on assets over the last 3 years. Customers take 60 days to pay, and stock sits for 71 days on average. At FY25 sales of ₹848 Cr, each day of that cycle ties up about ₹2.3 Cr, so roughly ₹163 Cr is tied up in the business at any time. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 71 days. Customers pay about 60 days after that. Suppliers are paid at 61 days. Together that makes the 70-day cycle. Spending on assets: ₹185 Cr over the last 3 years, against ₹48.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹8.0 Cr (FY25): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Elantas Beck India's P/E ratio, and how does it compare with its own history? Elantas Beck India Ltd's P/E is 54.1×, near the high end of its own history: higher than 81% of past readings. Its usual P/E (the middle reading) is 43.0×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +5.9% while the price moved +32.9%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +28.3% a year; about +20.2% a year came from earnings growth and about +8.1 percentage points from the multiple (the market paying more); over 10 years the price moved +21.6% a year; about +13.5% a year came from earnings growth and about +8.1 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 3.2% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Elantas Beck India business getting better or worse? Elantas Beck India Ltd's business is turning around. Profit growth has swung from −6.1% at its low to +35.5%, improving for 4 quarters in a row, with ROCE steady at 21.0%. This is based on 9 quarters of 4 measures, with some gaps. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Elantas Beck India earn on its capital? Elantas Beck India Ltd earned a ROCE of 21% in FY25. That is up from a low of 17% in FY21. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 17.5% net margin and 0.73× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 17.5% net margin × 0.73× asset turnover × 1.16× leverage (assets divided by equity) ≈ 14.8% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 3.2% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Elantas Beck India have too much debt? Elantas Beck India Ltd had ₹0.0 Cr of borrowings against ₹1,008 Cr of equity in FY25, so its debt is 0.00× its equity. Its operating profit is more than 100 times its interest bill. Over 5 years borrowings went from ₹0.0 Cr to ₹0.0 Cr. Over the last 3 of those years it spent ₹185 Cr on assets. The spending on assets is being paid for from cash, not new debt. ## What is the Elantas Beck India shareholding pattern? No group of Elantas Beck India Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved +0.6 points over the same period, to 12.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −0.6 points over 8 quarters, to 0.1%; Domestic institutions: +0.6 points over 8 quarters, to 12.5%; Promoters: +0.0 points over 8 quarters, to 75.0%. ## How far is Elantas Beck India from balance-sheet trouble? For Elantas Beck India Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Elantas Beck India rank in its industry? 57.1 out of 100, rank 6 of 20 in Chemicals - Organic, with 67% of the evidence available. Elantas Beck India Ltd scores 57.1 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 6. A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. The four parts add up to the total exactly: 20.7 + 18.1 + 6.5 + 11.8 = 57.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Elantas Beck India compared with? Elantas Beck India ranks 6 of 20 Chemicals - Organic companies on the 4-Factor Sector Score, with 57.1 out of 100. 1. [Nitta Gelatin India Ltd](https://www.sectoralpha.in/stocks/nitta-gelatin-india-ltd) NITTAGELA · quiet · Most evidence points up · 85% evidence 76.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.4/35 · Revenue 15% · Profit 49.4% · Operating margin change 9 points · 100% evidence Capital efficiency 21.3/25 · ROCE 27.7% · Operating margin 28% · 100% evidence Valuation 13.2/20 · P/E 12.1× · PEG 0.95 · 100% evidence Relative strength 12.0/20 · Lead over its industry n/a · Lead over NIFTY 500 35.5% · 1 year n/a · 25% evidence · 5 of 12 weeks ahead Exact sum: 30.4 + 21.3 + 13.2 + 12 = 76.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Indo Amines Ltd](https://www.sectoralpha.in/stocks/indo-amines-ltd) INDOAMIN · losing its lead · Most evidence points up · 81% evidence 66.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.8/35 · Revenue 13.3% · Profit 24.2% · Operating margin change 3 points · 88% evidence Capital efficiency 16.8/25 · ROCE 18.9% · Operating margin 14% · 100% evidence Valuation 19.0/20 · P/E 10.6× · PEG 0.32 · 100% evidence Relative strength 9.5/20 · Lead over its industry n/a · Lead over NIFTY 500 2.3% · 1 year -10.4% · 25% evidence · 4 of 12 weeks ahead Exact sum: 20.8 + 16.8 + 19 + 9.5 = 66.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Valiant Organics Ltd](https://www.sectoralpha.in/stocks/valiant-organics-ltd) VALIANTORG · breaking out · Evidence leans up · 78% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 1.5% · Profit 100% · Operating margin change 6 points · 83% evidence Capital efficiency 9.0/25 · ROCE 5.5% · Operating margin 18% · 76% evidence Valuation 10.9/20 · P/E 23.2× · PEG n/a · 50% evidence Relative strength 19.8/20 · Lead over its industry 24.1% · Lead over NIFTY 500 48.6% · 1 year 39.6% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21.4 + 9 + 10.9 + 19.8 = 61.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [OCCL Ltd](https://www.sectoralpha.in/stocks/occl-ltd) OCCLLTD · breaking out · Too little evidence to rank firmly · 56% evidence 59.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 40.6% · Profit 100% · Operating margin change 7 points · 83% evidence Capital efficiency 12.3/25 · ROCE 13% · Operating margin 28% · 76% evidence Valuation 11.1/20 · P/E 11× · PEG n/a · 15% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 45.3% · 1 year n/a · 25% evidence · 12 of 12 weeks ahead Exact sum: 23.6 + 12.3 + 11.1 + 12.1 = 59.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [BASF India Ltd](https://www.sectoralpha.in/stocks/basf-india-ltd) BASF · quiet · Evidence leans up · 71% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 6.5% · Profit 62.4% · Operating margin change 4 points · 88% evidence Capital efficiency 11.7/25 · ROCE 14.5% · Operating margin 10% · 100% evidence Valuation 14.1/20 · P/E 21.4× · PEG n/a · 50% evidence Relative strength 7.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -13% · 1 year -30.9% · 25% evidence · 5 of 12 weeks ahead Exact sum: 23.8 + 11.7 + 14.1 + 7.7 = 57.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. Elantas Beck India Ltd this page ELANTAS · leader · Evidence leans up · 67% evidence 57.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 18.7% · Profit 35.5% · Operating margin change 1 points · 95% evidence Capital efficiency 18.1/25 · ROCE 21.2% · Operating margin 23% · 76% evidence Valuation 6.5/20 · P/E 54.1× · PEG n/a · 50% evidence Relative strength 11.8/20 · Lead over its industry n/a · Lead over NIFTY 500 31.9% · 1 year 33.1% · 25% evidence · 12 of 12 weeks ahead Exact sum: 20.7 + 18.1 + 6.5 + 11.8 = 57.1 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 7. [Fine Organic Industries Ltd](https://www.sectoralpha.in/stocks/fine-organic-industries-ltd) FINEORG · leader · Evidence leans up · 96% evidence 56.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.9/35 · Revenue 7.1% · Profit 5.8% · Operating margin change 4 points · 88% evidence Capital efficiency 17.8/25 · ROCE 21.5% · Operating margin 25% · 100% evidence Valuation 15.0/20 · P/E 35.3× · PEG 0.58 · 100% evidence Relative strength 9.9/20 · Lead over its industry -7.6% · Lead over NIFTY 500 12.4% · 1 year 13.8% · 100% evidence · 9 of 12 weeks ahead Exact sum: 13.9 + 17.8 + 15 + 9.9 = 56.6 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 8. [Laxmi Organic Industries Ltd](https://www.sectoralpha.in/stocks/laxmi-organic-industries-ltd) LXCHEM · quiet · Evidence leans up · 81% evidence 54.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 5.5% · Profit 26% · Operating margin change 7.6 points · 88% evidence Capital efficiency 10.8/25 · ROCE 4.7% · Operating margin 12% · 100% evidence Valuation 13.1/20 · P/E 33.8× · PEG 1.14 · 100% evidence Relative strength 9.2/20 · Lead over its industry n/a · Lead over NIFTY 500 1.8% · 1 year -22% · 25% evidence · 10 of 12 weeks ahead Exact sum: 21.1 + 10.8 + 13.1 + 9.2 = 54.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Balaji Amines Ltd](https://www.sectoralpha.in/stocks/balaji-amines-ltd) BALAMINES · quiet · Evidence leans up · 78% evidence 53.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.2/35 · Revenue 11.1% · Profit 41.6% · Operating margin change 10 points · 83% evidence Capital efficiency 13.1/25 · ROCE 11% · Operating margin 25% · 76% evidence Valuation 9.1/20 · P/E 28× · PEG n/a · 50% evidence Relative strength 8.2/20 · Lead over its industry -2.5% · Lead over NIFTY 500 15.2% · 1 year 25.3% · 100% evidence · 6 of 12 weeks ahead Exact sum: 23.2 + 13.1 + 9.1 + 8.2 = 53.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Fairchem Organics Ltd](https://www.sectoralpha.in/stocks/fairchem-organics-ltd) FAIRCHEMOR · quiet · Evidence leans up · 100% evidence 53.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 17.1% · Profit 100% · Operating margin change 6.2 points · 100% evidence Capital efficiency 7.0/25 · ROCE 3.3% · Operating margin 10% · 100% evidence Valuation 13.0/20 · P/E 32.7× · PEG 0.84 · 100% evidence Relative strength 3.0/20 · Lead over its industry -15.4% · Lead over NIFTY 500 3.2% · 1 year -15.9% · 100% evidence · 9 of 12 weeks ahead Exact sum: 30.3 + 7 + 13 + 3 = 53.3 · What this means: Earnings are strong; relative strength in its sector is -15.4% and the one-year return is -15.9%. 11. [Sigachi Industries Ltd](https://www.sectoralpha.in/stocks/sigachi-industries-ltd) SIGACHI · breaking out · Evidence leans down · 100% evidence 49.4 out of 100 Growth Capital Valuation Relative
12. [GFL Ltd](https://www.sectoralpha.in/stocks/gfl-ltd) GFLLIMITED · breaking out · Evidence leans down · 71% evidence 48.6 out of 100 Growth Capital Valuation Relative
13. [Jyoti Resins and Adhesives Ltd](https://www.sectoralpha.in/stocks/jyoti-resins-and-adhesives-ltd) JYOTIRES · basing · Evidence leans down · 74% evidence 43.7 out of 100 Growth Capital Valuation Relative
14. [Foseco India Ltd](https://www.sectoralpha.in/stocks/foseco-india-ltd) FOSECOIND · leader · Evidence leans down · 81% evidence 41.1 out of 100 Growth Capital Valuation Relative
15. [Shree Ganesh Remedies Ltd](https://www.sectoralpha.in/stocks/shree-ganesh-remedies-ltd) SGRL · breaking out · Evidence leans down · 85% evidence 40.3 out of 100 Growth Capital Valuation Relative
16. [Oriental Aromatics Ltd](https://www.sectoralpha.in/stocks/oriental-aromatics-ltd) OAL · leader · Evidence leans down · 74% evidence 36.5 out of 100 Growth Capital Valuation Relative
17. [Gem Aromatics Ltd](https://www.sectoralpha.in/stocks/gem-aromatics-ltd) GEMAROMA · quiet · Too little evidence to rank firmly · 51% evidence 32.2 out of 100 Growth Capital Valuation Relative
18. [Sacheerome Ltd](https://www.sectoralpha.in/stocks/sacheerome-ltd) SACHEEROME · losing its lead · Too little evidence to rank firmly · 36% evidence 58.1 out of 100 Growth Capital Valuation Relative
19. [Shri Ahimsa Naturals Ltd](https://www.sectoralpha.in/stocks/shri-ahimsa-naturals-ltd) SHRIAHIMSA · leader · Too little evidence to rank firmly · 47% evidence 56.8 out of 100 Growth Capital Valuation Relative
20. [Citurgia Biochemicals Ltd](https://www.sectoralpha.in/stocks/citurgia-biochemicals-ltd) CITURGIA · Too little evidence to rank firmly · 25% evidence 34.3 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Chemicals - Organic](https://www.sectoralpha.in/sectors/chemicals-organic), all 20 compared on one page. ## Which companies are close to Elantas Beck India in size? Elantas Beck India is the 3rd largest of 20 Chemicals - Organic companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Fine Organic Industries and BASF India. Just below it: Balaji Amines, Foseco India, Laxmi Organic Industries and Oriental Aromatics. ### Chemicals - Organic companies close in size

1. [Fine Organic Industries Ltd](https://www.sectoralpha.in/stocks/fine-organic-industries-ltd) ₹15,480 crore
2. [BASF India Ltd](https://www.sectoralpha.in/stocks/basf-india-ltd) ₹13,198 crore
3. Elantas Beck India Ltd ₹6,417 crore
4. [Balaji Amines Ltd](https://www.sectoralpha.in/stocks/balaji-amines-ltd) ₹5,721 crore
5. [Foseco India Ltd](https://www.sectoralpha.in/stocks/foseco-india-ltd) ₹4,419 crore
6. [Laxmi Organic Industries Ltd](https://www.sectoralpha.in/stocks/laxmi-organic-industries-ltd) ₹4,245 crore
7. [Oriental Aromatics Ltd](https://www.sectoralpha.in/stocks/oriental-aromatics-ltd) ₹1,916 crore

[All 20 Chemicals - Organic companies, largest first](https://www.sectoralpha.in/sectors/chemicals-organic#all-companies)

### Companies close in size in other industries

1. [Suprajit Engineering Ltd](https://www.sectoralpha.in/stocks/suprajit-engineering-ltd) ₹6,502 crore · Auto Ancillaries - Diversified
2. [Bengal & Assam Company Ltd](https://www.sectoralpha.in/stocks/bengal-assam-company-ltd) ₹6,452 crore · Finance & Investments - Others
3. Elantas Beck India Ltd ₹6,417 crore
4. [Sapphire Foods India Ltd](https://www.sectoralpha.in/stocks/sapphire-foods-india-ltd) ₹6,397 crore · Quick Service Restaurant - QSR
5. [Gujarat Ambuja Exports Ltd](https://www.sectoralpha.in/stocks/gujarat-ambuja-exports-ltd) ₹6,388 crore · Agricultural Processing - Maize

## What else do people ask about Elantas Beck India? ### What is Elantas Beck India's share price today? Elantas Beck India Ltd's share price is ₹12,756.00, +32.9% over the past year. The whole company is worth ₹10,112 Cr on the market. In the last 52 weeks it traded between ₹7,571 to ₹14,521; today it is 75% of the way up from the low, 14.9% above its 200-day average (as of 3 November 2026). ### What were Elantas Beck India's latest quarterly results? Elantas Beck India Ltd reported revenue of ₹265 Cr and net profit of ₹46.0 Cr for the Sep 2026 quarter. Revenue rose 22.1% and profit rose 27.8% compared with a year earlier. Earnings per share were ₹57.46. The operating margin was 23.0%, 1.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Elantas Beck India's market cap? Elantas Beck India Ltd's market capitalisation is ₹10,112 Cr at a share price of ₹12,756.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Elantas Beck India performing? Elantas Beck India Ltd's share price has been rising for 19 weeks. In its latest quarter, revenue rose 22.1% and profit rose 27.8% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 15 weeks running (as of 3 November 2026). ### Will Elantas Beck India's share price go up? This page does not forecast Elantas Beck India Ltd's share price. What it shows instead: the share price is ₹12,756.00, and it has been rising for 19 weeks. Its P/E of 54.1× is higher than 81% of its own last 11 years (as of 3 November 2026). ### Where is Elantas Beck India in its business cycle? Elantas Beck India Ltd's FY25 operating margin was 20.0%, against a 12-year range of 12.0% to 22.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 23.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Elantas Beck India story? The main question: the share price moved +32.9% in a year while yearly earnings per share moved +5.9%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Elantas Beck India a stock worth studying right now? What the numbers show: Elantas Beck India Ltd's share price has risen faster than its earnings: +32.9% in a year, against +5.9% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india

This is research, not advice. We’re not SEBI-registered.